Close Menu

NEW YORK – A federal appeals court has denied Illumina's appeal seeking a permanent injunction against Roche's Ariosa Diagnostics in a 2014 lawsuit where a jury awarded Illumina $26.7 million for patent infringement related to non-invasive prenatal testing (NIPT) technology. The court also denied Ariosa's cross-appeal, upholding the judgment.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.